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Introduction
Hair is one of the vital fragments of the body derived 
from ectoderm of skin and contains a protein called 
keratin that is produced in hair follicles in the outer layer 
of skin (1-3). Hair loss or alopecia is one of the most 
common problems of many communities causing many 
economical and physiological problems (4). Alopecia is 
a dermatological disorder that has been known for more 
than 2000 years and is considered a common problem in 
cosmetics as well as primary health care practice (1,2). 
Normally, 50-100 hairs are lost per day and an increase 
in lost hairs up to more than 100 is considered hair loss 
(3-5). There are many types of hair loss and the most 
common type is referred to as male-pattern baldness 
(when it  occurs in women it is called female-pattern 
baldness) which affects over 95% of people with hair loss 
(6,7). Androgenetic alopecia is hereditary thinning of the 
hair induced by androgens in genetically predisposed men 
and women (1,2,8). Alopecia areata is an autoimmune 
illness affecting nearly 2% of the US population. Alopecia 
areata affects both sexes similarly and occurs at all ages, 
although children and young adults are affected most 
often (6-8). The treatment of hair loss is sometimes 
difficult because of deficient efficacy and limited options 
(4). Two drugs have been approved by the Food and Drug 
Administration (FDA) for the treatment of androgenetic 
alopecia, minoxidil and finasteride. Minoxidil is a special 
lotion applied twice a day to enhance blood supply to the 
follicles and papillae and encourage hair growth (6,7). 
Minoxidil is a powerful vasodilator and appears safe for 
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Implication for health policy/practice/research/medical education:
Eugenol comprising about 70% of clove essential oil exerts an androgenic and antibacterial activities and stimulates hair root to 
feed and hence could be a used by humans for these purposes.
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Introduction: From a consumer perspective, developing a hair care formulation that offers multi-
purpose products to enhance routine hair care such as conditioning, cleaning and grooming hair 
and stimulating hair follicles is important. Eugenol comprising about 70% of clove essential oil 
shows an androgenic activity and stimulates hair root to feed and hence could be a good candidate 
for developing an anti-hair loss formulation. Thus in hair research, hair follicle is of great interest. 
The aim of this study was to develop a self-emulsifying product containing eugenol in emu oil as 
a carrier.
Methods: Eugenol was identified in clove oil extraction by UV spectrophotometer. Emu oil was 
characterized according to national oil standards. All formulations were prepared and best one 
was selected for further pharmaceutical examinations such as pH, particle size, content uniformity 
and drug release. The optimum formulation was clinically evaluated on rats back compared with 
minoxidil standard lotion as a positive control and distilled water as a negative control.
Results: The selected formulation was demonstrated to condition hair with grooming and 
enhanced hair growth with longer lag time compared with minoxidil but after one week the hair 
growth accelerated. 
Conclusion: The formulation containing clove oil in emu oil self-emulsion shows a conditioning 
and grooming property with hair shaft repair and hair growth.
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long-term treatment and anagen phase of hair growth, 
and enlarges miniaturized and suboptimal follicles (8-11). 
The main adverse reactions are itching, contact dermatitis 
and dryness (10,12). Finasteride (Propecia)®, taken once 
a day, is a an oral medication that specifically decreases 
the production of dihydrotestosterone by blocking the 
enzyme vital to its formation. Treatments of alopecia areata 
include steroids (injection or topical ointment), minoxidil 
and anthralin cream. Corticosteroid may be injected into 
the bald patches or applied directly to the skin as a lotion 
to stimulate hair growth. Usually, hair begins to grow 
again within some weeks, and the injections are repeated 
within a month. Anthralin cream may also be applied to 
the hairless area; this irritant is used every day and rinsed 
off an hour later. The treatment usually encourages hair 
growth within two to three months (6,7).
The purpose of this study is to prepare self-emulsion 
using appropriate amounts of eugenol and emu oil as 
an emollient agent to reduce skin irritation and increase 
penetration. 
The emu oil can simply penetrate into skin because of 
containing large amounts of oleic acid and similarity 
to human sebum. It is an excellent transdermal carrier 
which penetrates into the skin, increases the potency of 
topical medications such as eugenol and provides long-
lasting effectiveness. Emu oil helps to repair scar tissue. 
It also accelerates the development of fresh skin cells 
by delivering the required bio-nutrients deep into skin 
where fresh cells form and decrease the buildup of wound 
tissue (13,14).
Materials and methods
Clove essential oil (eugenol) was supplied from Golchai 
Co. (Iran), cetrimonium chloride and coconut fatty acid 
diethanolamin were supplied from Merck Co. (Germany) 
and polysorbate 80 from (Croda Chemicals Ltd, UK), 
Emu oil was obtained from Abyaneh Cosmetic Company 
(Isfahan, Iran). All other ingredients used in this study 
were of analytical grade.
Authentication of eugenol
Eugenol was authenticated according to USP and BP 
pharmacopeia by UV spectroscopy.
Preparation of standard curve
In order to generate standard curve, 19 mg of eugenol was 
accurately weighed and solubilized in 19 ml ethanol 96%. 
This solution was diluted to obtain standard solutions 
at the concentrations of of 5-50 µg/mL. The absorbance 
of standard solutions was measured by UV/Visible 
spectrophotometer (Shimadzu, UV mini-1240CE) at 282 
nm and the standard curve was generated (Figure 1).
Preparation of self-emulsion
To develop a stable emulsion, the formulations were 
developed with different amounts of emulsifiers with 
experimental design. Nine experiments were suggested 
by software according to input variable and expected 
output specification. The compositions of prepared 
formulations are shown in Table 1. The oil phase of 
emulsion was prepared by mixing emu oil and eugenol 
1%. The oil phase was separately heated to 40-50ºC to 
achieve homogeneity. Then the aqueous phase was added 
to the oily phase with continuous stirring at 800 rpm to 
obtain a clear, transparent micro emulsion. Based on the 
primary evaluation of organoleptic and centrifuge test of 
the prepared emulsions, formulation 6 (F6) was selected 
to finish evaluation.
Evaluation of the selected formulation
The following physicochemical parameters were used for 
the evaluation of formulation: 
Determination of particle size
The particle size of emulsion was determined by zeta 
analyzer (Malvern Instruments Ltd.).
Organoleptic evaluation
The prepared self-emulsion was examined visually for 
color and homogeneity.
Centrifuge test
The prepared formulation was centrifuged at 3000 rpm 
for 30 minutes (HETTIC D-7200, Germany) 24 hours 
after preparation and then once a week for 28 days (15).
Determination of pH
pH of the prepared formulation was measured by a 
digital pH meter (Metrohm, Switzerland) (15). The 
determinations were carried out in triplicate and the 
average value of three readings was recorded.
Freeze-thaw cycle
Freeze-thaw treatment of the emulsion was performed 
closely after preparation. Samples (20 mL) were stored at 
-20°C for 48 hours. The frozen samples were subsequently 
thawed at room temperature for 48 hours (16). This test 
carried out in triplicate for each sample.
Drug content
To determine drug content, a certain amount of emulsion 
(10 puffs equal to 1 g of emulsion) was collected and 
introduced into a screw-capped tube. Then phosphate 
buffer (pH 7.4) was added to the emulsion up to the 
volume of 50 mL. After shaking for 2 hours in orbital 
water bath shaker (Gallen KAMP, Germany) at 37°C, 
the diluted emulsion was filtered through a 0.45 µm 
Whatman filter. The amount of eugenol was determined 
spectrophotometrically (Shimadzu, UV mini-1240CE) by 
measuring the absorbance of the filtrate at 282 nm (17). 
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Figure 1. Ultraviolet spectrum of standard eugenol.
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This procedure was performed for an emulsion system 
containing no drug as the blank.
Stability test
The stability was examined at 8ºC (in refrigerator), 25ºC 
(in room) and 40ºC (in oven) (15,18). At 1 week intervals 
for 1 month, drug content and physical appearance 
(organoleptic characteristics) were examined.
In-vitro drug release study
Franz diffusion cell (25 mL volume) was used to study the 
drug release. The receiver compartment was filled with 
ethanol 96% obtained after examination of sink condition 
and 10 puffs (equal to 1 g emulsion) of self-emulsion were 
applied on the surface of cellulose acetate membrane. 
The membrane was clamped between the donor and the 
receiver compartments. The donor compartment was 
exposed to the receiver compartment at 37°C temperature. 
The solution on the receiver compartment was stirred by 
magnetic stirrer. At predetermined time intervals, 0.5 mL 
of solution from receiver compartment was pipetted out 
and closely replaced with fresh 0.5 mL of receiver medium. 
After appropriate dilution the drug concentration on the 
receiver medium was determined spectrophotometerically 
at 282 nm. The experiment was carried out in triplicate. 
To study drug release kinetics, data obtained from in vitro 
investigation of release were fitted to the zero, first and 
Higuchi kinetic models (16,19,20).
Kinetic analysis of drug release
To study drug release kinetics, data obtained from in 
vitro investigation of release were fitted in Zero, First and 
Higuchi kinetic models (20-22).
Animal study
Male Wistar albino rats weighing 200-250 g were used for 
in vivo studies. They were kept in standard environmental 
conditions with free access to special diet and drinking 
water. All animal experiments were carried out in 
accordance with the guidelines of Institutional Animal 
Ethics Committee of Isfahan University of Medical 
Sciences. 
Skin irritation test
Three healthy male rats were selected for this study. Each 
rat was separately kept in a cage during the study period. 
The hair from the back of each rat (test sites of 1 cm2) 
was shaved on the side of the spine to expose sufficiently 
large test areas. The test sites were cleaned with surgical 
spirit and 1 g of F6 was applied over the respective test 
sites of one side of the spine. The test sites were observed 
for erythema and edema for 48 hours after application 
(23,24).
Application of test formulations for hair growth evaluation
The rats were divided into four groups of five each and a 
4 cm² area of dorsal section of all rats was shaved. Group 
I (control) received no treatment. Group II (positive 
control) was treated with standard formulation including 
1 mL of 5% minoxidil ethanolic solution applied on the 
shaved area once a day. Group ΙΙΙ (blank) was treated with 
the prepared formulation (1 g) without eugenol applied 
on the shaved area once a day, and Group IV animals 
were treated with 1 g of prepared formulation under study 
once a day. All treatments lasted for 28 days. During the 
treatments, hair growth initiation and completion time 
was observed. Hair was randomly plucked from the test 
area of each rat on days 7, 14, and 21 of the experiment. 
The length of 10 hairs per animal was estimated and the 
average length was recorded (Table 4). At the completion of 
the treatments, two rats from each group were euthanized 
and skin biopsies were taken from shaved areas. Specimen 
was preserved in 10% formalin. Tissues were embedded 
in paraffin wax, sectioned into uniform thickness of 10 
µm and stained with hematoxylin and eosin. The sections 
were evaluated microscopically for the number of hair 
follicles (24,25).
Ethical issues
All the animals were handled in accordance with the 
internationally accepted principles and guidelines for 
the care and use of laboratory animals in 2010 (26) and 
the Ethics Committee of Isfahan University of Medical 
Sciences.
Results 
Authentication of eugenol
UV spectrum eugenol
As Figure 2 shows, the maximum absorption of eugenol 
at 5-50 μg/mL concentrations in ethanol 96% at 200-400 
nm was seen at 282 nm. The UV spectrum obtained from 
eugenol sample in ethanol 96% solution was similar to the 
standard eugenol. 
Self-emulsion preparation
As Table 1 shows, the best formulation was F6 containing 
eugenol (1%), emu oil (5%), cetrimonium chloride (0.5%), 
Table 1. Self-emulsion formulation (oil/water%)
Formulation
Ingredient (g) 1 2 3 4 5 6 7 8 9
Eugenol 1 1 1 1 1 1 1 1 1
Emu oil 5 5 5 5 5 5 5 5 5
Cetrimonium chloride 0.5 2 2 1 1 0.5 2 1 0.5
Cremophor 6 2 6 2 6 2 4 4 4
Cetyl Alcohol 4 4 3 3 2 2 2 4 3
Tween 80 5 3 1 5 3 1 5 1 3
Coconut fatty acid diethanolamin 2 2 2 2 2 2 2 2 2
Canola oil up to 100 ml 76.5 81 80 81 80 86.5 79 82 81.5
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cremophor (2%), cetyl alcohol (2%), tween 80 (1%), 
coconut fatty acid diethanolamin (2%) and canola oil (up 
to 100%). The oil phase was separately heated to 50-60°C. 
Then the aqueous phase (95 mL water) was added to 5 mL 
of oil phase with continuous stirring. When the emulsion 
cooled to room temperature, control tests were done.
Quality control tests of selected formulation
The F6 had light white color and a specific odor (Table 
2). Microscopic examination of the prepared formulation 
revealed homogeneity of globule and internal phases.
Determination of particle size of the prepared emulsion
In order to reach to a particle size less than 10 μm able to 
penetrate into follicular structure, the average particle size 
of F6 in the present study was approximately 7 μm. 
In-vitro release profile of eugenol from the prepared 
formulation
The in vitro investigation of the drug release of the 
formulation presented a controlled drug release for a 
period of 4 hours (Figure 3). 
Kinetic analysis of drug release
The in vitro investigation of drug release of the formulation 
exhibited release for a period of 4 hours. According to the 
release based on the correlation coefficient, first-order 
kinetic is dominant. 
Stability studies
According to Table 3, F6 did not show changes in color 
and phase separation at 8°C, 25°C and 40°C within one 
month. The drug content of the formulation was found 
to be in the range of 96.5%-98% at 8°C, 25°C and 40°C, 
which represents a permitted range (100 ± 5) percentage 
of variation (27). 
Skin irritation test
Evaluation of the studied formulation for possible 
irritation on intact skin of rats showed no erythema or 
edema on outer layer of skin, indicating the safety of the 
prepared F6 containing 1% eugenol for topical application. 
Hair growth activity evaluation
Hair growth initiation significantly increased by treatment 
with standard drug and the studied formulation. The hair 
growth was initiated in denuded area on day 15 in control 
rats, while it was initiated after the first week in positive 
control group and in the F6-treated group. However, the 
completion time was not affected by different treatments 
in this study. Table 4 shows the average hair length of each 
group at different time intervals during the experimental 
period.  The average hair length significantly increased 
with different treatments compared to the control group. 
Discussion
Self-emulsifying drug delivery systems (SEDDSs) are 
mixtures of oils, surfactants and co-surfactants. Sometimes 
co-solvents are also used to increase the solubility. 
Therefore, SEDDSs have also become an important tool 
in novel drug delivery in recent years. SEDDSs emulsify 
spontaneously and produce fine oil-in-water emulsions if 
introduced into an aqueous phase under gentle agitation 
(28,29).
The prepared emulsion formulation, with good 
characteristics based on pharmaceutical evaluation, 
consists of eugenol, emu oil, setrumonium chloride, 
cremophor, cetyl alcohol, tween 80, coconut fatty acid 
diethanolamine, canola oil and water.
A salient feature of this formulation is use of emu oil. Emu 
oil is compatible with human skin lipid and can be used 
as an enhancer and drug carrier to help the penetration of 
active ingredients through the skin.
The results showed that the effect of emulsion (F6) on 
hair growth began on day 6 after the treatment and 
commercial minoxidil 5% solution exerted its effect on 
Figure 2. Eugenol standard curve in ethanol 96%.
Table 2. Physicochemical evaluation of formulation
Parameters Results
Physical appearance Light white color and an specific odor, 
complete homogeny
Centrifuge +++
Freeze-thaw +++
pH 5.873 ± 0.146
Drug content 98.09 ± 0.36
+: poor after test, ++: good after test, +++: excellent after test.
Figure 3. In vitro release of eugenol through cellulose acetate 
membrane.
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day 3 after application, but the hair growth accelerated 
after one week. The animals which were treated with 
blank formulation showed greater conversion of follicle 
compared with the control group on day 28 after the 
treatment. This may be due to the effect of emu oil on 
hair growth and gentle rubbing of the shaved skin area 
during treatment which may enhance blood flow to the 
hair follicles. A clinical study on the activity of emu oil 
on hair growth revealed that there was a 20% increase in 
DNA synthesis, hair and skin re-growth stimulated and 
hair follicles robustness increased (30). In a study on rats, 
when treated similarly with water, the whole denuded area 
was covered at the end of the treatment course because of 
gentle rubbing of the site (31). 
Conclusion
The prepared eugenol in self-emulsion formulation was 
stable by different pharmaceutical evaluations. The emu 
oil used in this formulation could increase penetration. 
This formulation could be a good candidate for hair loss 
treatment.
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Table 3. Stability of the studied parameters of selected formulation
Parameters
Result
Condition Initial 7 days 14 days 28 days
Physical appearance
8 °C √ √ √ √
25 °C √ √ √ √
40 °C √ √ √ √
Drug content (mean ±SD)
8 °C 98.07% ± 0.41 97.7 ± 1 97.6 ± 1.02 97 ± 1.07
25 °C 98.07% ± 0.41 97.9 ± 1.02 97.5 ± 1.16 97.56 ± 1.16
40 °C 98.07% ± 0.41 97 ± 1 96.88 ± 1.023 96.5 ± 1.07
√: Unchanged
Table 4. Mean (standard deviation) hair length in different groups 
at various intervals
Group Day 7 Day 14 Day 21 Day 28
Control - - 0.445±0.089 0.57±0.115
Standard 1.08±0.113 1.58±0.122 2.16±0.183 2.5±0.163
Blank - 0.51±0.061 0.93±0.105 1.11±0.11
Treatment 0.53±0.1 1.07±0.082 2.2±0.188 2.85±0.164
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